We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 28. | 장 마감 후 (AMC) | $0.12 | — | — | $67.1M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.08 | — | — | $48.56M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.24 | — | — | $137.93M |
Consensus PT $50.78 · 9 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 30. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 04. 30. | Citizens | — | 의견 유지 | Market Outperform → Market Outperform | — | Citizens: Market Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.2 | — | — | $89.29M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 682,104 | $22.6B | 0.02% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 433,473 | $14.19B | 0.02% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Stored first · Google News · Yahoo Finance (English)
Precision Trading with Axogen Inc. (AXGN) Risk Zones - Stock Traders Daily
Precision Trading with Axogen Inc. (AXGN) Risk Zones Stock Traders Daily
Axogen (AXGN) Valuation Check After Strong Recent Share Price Momentum - simplywall.st
Axogen (AXGN) Valuation Check After Strong Recent Share Price Momentum simplywall.st
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam - Yahoo Finance
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam Yahoo Finance
Axogen director sells shares after option exercise | AXGN Insider Trading - Stock Titan
Axogen director sells shares after option exercise | AXGN Insider Trading Stock Titan
Axogen (AXGN) CMO sells 4,000 shares around $43 per share - Stock Titan
Axogen (AXGN) CMO sells 4,000 shares around $43 per share Stock Titan